Clinical laboratories large and small are experiencing increased scrutiny from the federal government, states and private insurers.  This focus has developed because payers have identified several areas in which they believe improper billing is occurring.

In this presentation, Dr. Daly discusses areas of regulatory concern and individual liability.

Send this to a friend